Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yes noticed. Any coincidence that ARIX are due to post final results this week?
Has anyone else noticed the RNS's from Arix? Today Acacia go over 21% (at 30% they must start a takeover bid). Who are Acacia? About Us: Acacia Research seeks to acquire undervalued businesses with a primary focus on mature technology, life sciences, industrial and certain financial ...
I think this more than the promise of some dividends or tender offer will stoke the share price. A good time to top up here ahead of that?
GLA
If they haven't got an immediate use for the cash wouldn't it be sensible to return some of this to shareholders?
With cash worth 99p per share and a share price of 114p (mid) even if half of the cash was returned the share price shouldn't drop by an equivalent amount.
Actually a dividend policy of, say 5% of nav p.a., might turn around our fortunes.
Best wishes
Nick
I’d really like to see Mr Chin toppling up on some holdings. If he has a strong conviction then why are we sitting on so much cash? (Still)
If you consider the cash and listed stocks they total about £1.30. So if you bought at today’s insane price then you could make 17p a share Even If 100% of the unlisted is garbage (it’s not).
The depressed valuations of much of biotech is insane!!
Good to see intention to publish regular updates on unaudited NAV.
Must have read your post SGD27!
A reassuring update and interesting to see progress in the unlisted portfolio [now worth more than the listed portfolio]
Surely it's time for the discount [c.40%] to start narrowing a bit.
Results [due next Thursday] should make for interesting read.
Hi chique,
Yes, NAV in December won't mean much, will it, given the hits we've taken since (LogicBio, Harpoon, Imara). I don't know why they can't provide more frequent NAV updates, say weekly, or even just monthly. By comparison IBT provide them every day, which has the added bonus that HL provide SP+NAV & Premium/Discount charts:
https://www.hl.co.uk/shares/shares-search-results/i/international-biotechnology-trst-ord-25p
If you're on speaking terms with them, perhaps you could suggest it :-)
spoke to Arix in Feb22 they said results in march
I fear NAV is going to be a considerable drop , but NAV will only be up to December I think
Annual results (over)due now :
https://www.lse.co.uk/rns/ARIX/closed-period-notification-q86krodcmbj9hss.html
"... annual financial results for the year ended 31 December 2021, with an expected publication date of early April, to be confirmed."
Dates for previous years:
09/03/21
10/03/20
28/03/19
23/04/18
28/04/17
Any news or views here of late? I am wondering why I bothered buying here last year?
Looks like another dud investment, falling the best part of 30% on news they are discontinuing a study on their potential prostate cancer drug. Shaves another penny or so off the NAV. No doubt the SP will lose a multiple of this.
Managed to get an extra 4000 - but only offering max 1000 now
This has been telephone only now for 10 minutes - they have run out of shares
apologies - I was too lazy to look , yes it's all there :-)
Yes it's quite a large article spanning 3 column pages
Those quotes are in the article I linked, but maybe there was more in the magazine?
This is a small part of write up
Using the latest market prices, Arix’s listed portfolio is currently worth £51mn (39.5p a share), a sum that accounts for less than a quarter of my spot NAV estimate of £239mn (185p a share). The unlisted portfolio has a pro-forma valuation of £60mn(46.5p a share) and Arix has net cash of around £127.8mn (99p a share) after accounting for £30mn of investments made in the second half of 2021, estimated operating expenses of £2.5mn during the six-month period, and £3.5mn of share buybacks.
This means that the cash pile backs up 83 per cent of the company’s £154mn market capitalisation, so the unlisted and listed portfolios are in the price for only £26mn even though they have a combined value of £111mn.
The bottom line is that cash in the bank and the valuable Artios stake back up all of Arix’s market capitalisation of £154mn,
so you are getting a free ride on the whole listed portfolio worth £51mn and £35mn of other unlisted holdings, too.
The de-rating has gone too far, and bottom fishers should be rewarded. Buy
Not that one it's in 18th Jan 22 edition magazine - quite a good write up
Many thanks, chique.
https://www.investorschronicle.co.uk/ideas/2022/02/17/2021-bargain-shares-portfolio-review/
(If not a subscriber, try going there via google "2021 Bargain Shares Portfolio Review".)
IC buy tip today - oversold and cash alone worth 99p of SP
Preopen down 34% due to triaL HALT
Have been tracking IMRA, AUTL , HARP and LOGC - all down an average of 78% last year - some over 80% but AUTL down 56%
Acacia adding, and have now risen above 20%. (RNS not showing here yet for some reason.)
https://www.investegate.co.uk/arix-bioscience-plc--arix-/eqs/notification-of-major-share-holding/20220111170404EVAES/
Maybe another tip from IC that they haven't made public yet?